Phillip Andrew Dennis - 17 Jun 2026 Form 4 Insider Report for NovaBridge Biosciences (NBP)

Reporting relationship: Chief Medical Officer
Issuer ticker: NBP
Reported as of: 17 Jun 2026
Net transaction value: -$5,606
SEC form: 4
Accepted by SEC: 22 Jun 2026, 17:23:50 UTC
Prior SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Xi-Yong (Sean) Fu as attorney-in-fact

Key filing fact

Phillip Andrew Dennis filed Form 4 for NovaBridge Biosciences (NBP) on 22 Jun 2026.

Key facts

This page summarizes Phillip Andrew Dennis's Form 4 filing for NovaBridge Biosciences (NBP).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Jun 2026, 17:23.

Change

Previous filing in this sequence was filed on 19 Mar 2026.
Current net transaction value: -$5,606.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002089237 Primary reporting owner

Dennis Phillip Andrew

Relationship: Chief Medical Officer
Address: C/O NOVABRIDGE BIOSCIENCES, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE
Signature: /s/ Xi-Yong (Sean) Fu as attorney-in-fact
Signature date: 22 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBP transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +23,695
Change %: +17%
Price
Shares after: 166,435
Date: 17 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

NBP transaction

Ordinary Shares

Sale

Transaction value: $5,606
Shares: -8,494
Change %: -5.1%
Price: $0.6600
Shares after: 157,941
Date: 18 Jun 2026
Ownership: Direct
Footnotes: F1, F5, F6, F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBP transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -10,302
Change %: -11%
Price: $0.000000^*
Shares after: 82,422
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,302
Exercise price
Footnotes: F1, F3, F8, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

Footnote F2

Reported securities are represented by 10,302 ADSs.

Footnote F3

Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

Footnote F4

Reported securities are represented by 72,363 ADSs.

Footnote F5

Reported securities are represented by 3,693 ADSs.

Footnote F6

Reported sales price represents the converted sales price of the ADSs of $1.51.

Footnote F7

Reported securities are represented by 68,670 ADSs.

Footnote F8

Reported securities represent ADSs.

Footnote F9

On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month.